Table 3.
Multivariate analysis of factors associated with the risk of progression among patients with NEC.
| HR (95%CI) | p Value | |
|---|---|---|
| Model 1: Rbinap | ||
| Lung primary (vs. other locations) | 1.39 (0.75–2.58) | 0.301 |
| SCNEC (vs. LCNEC) | 0.54 (0.29–1.03) | 0.06 |
| Ki-67 (each additional 1%) | 1.02 (1–1.03) | 0.028 |
| Extra-hepatic metastases (vs. absence) | 1.04 (0.62–1.75) | 0.87 |
| Rbinap (vs. Rbapp) | 0.57 (0.32–1.02) | 0.058 |
| Model 2: Rb < 150 | ||
| Lung primary (vs. other locations) | 1.31 (0.71–2.42) | 0.393 |
| SCNEC (vs. LCNEC) | 0.59 (0.31–1.1) | 0.097 |
| Ki-67 (each additional 1%) | 1.02 (1.00–1.04) | 0.014 |
| Extra-hepatic metastases (vs. absence) | 1.1 (0.66–1.84) | 0.712 |
| Rb < 150 (vs. Rb score ≥ 150) | 0.37 (0.17–0.8) | 0.012 |
| Model 3: p16high | ||
| Lung primary (vs. other locations) | 1.59 (0.82–3.09) | 0.167 |
| SCNEC (vs. LCNEC) | 0.54 (0.27–1.09) | 0.086 |
| Ki-67 (each additional 1%) | 1.02 (1–1.04) | 0.018 |
| Extra-hepatic metastases (vs. absence) | 1.19 (0.71–1.98) | 0.518 |
| p16high (vs. p16low) | 0.39 (0.19–0.79) | 0.009 |
HR, Hazard ratio; 95%CI, 95% confidence interval; SCNEC, small-cell neuroendocrine carcinoma; LCNEC, large-cell neuroendocrine carcinoma; NEN, neuroendocrine neoplasm.